XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Cash Flows Used In Operating Activities        
Net Loss $ (23,658,106) $ (59,882,054)    
Non-Cash Adjustments        
Depreciation and Amortization 2,342,483 3,265,636    
Stock-Based Compensation 4,496,088 8,459,005    
Loss on Fixed Asset Disposal   11,277    
Allowance for Credit Losses   540,000    
Impairment on Intangible Assets and Equity Investments   30,301,355    
(Increase) Decrease in Operating Assets        
Accounts Receivable 584,184 610,212    
Accrued Revenues in Excess of Billings 243,409 (322,461)    
Utility Improvement Refund   208,271    
Inventories 1,917,817 (825,303)    
Manufacturing Vendor Prepayments 216,268 95,133    
Prepaid Expenses and Other Assets (47,282) 199,343    
Increase (Decrease) in Operating Liabilities        
Accounts Payable 32,857 (911,358)    
Accrued Expenses 618,672 (1,700,548)    
Unearned Revenue (25,116) 149,044    
Income and Other Taxes Payable 43,891 85,251    
Net Cash Flows Used in Operating Activities (13,234,835) (19,717,197) $ (23,739,372) $ (26,277,824)
Cash Flows Used in Investing Activities        
Purchases of Fixed Assets (1,658,820) (1,129,120)    
Investments in Patents and Trademarks (381,614) (437,609)    
Investments in Licenses   (1,000,000)    
Investments in Other Assets (50,000)      
Net Cash Flows Used in Investing Activities (2,090,434) (2,566,729) (2,919,949) (19,280,966)
Cash Flows Provided by Financing Activities        
Proceeds from Sale of Preferred and Common Stock to Quanta 10,000,000 10,000,000    
Proceeds from Exercise of Stock Options 106,843      
Proceeds from ATM Program, Net 9,640,449      
Net Cash Flows Provided by Financing Activities 19,747,292 10,000,000    
Net Increase (Decrease) in Cash and Cash Equivalents 4,422,023 (12,283,926)    
Cash and Cash Equivalents - Beginning of Period 18,186,506 26,555,592 26,555,592  
Cash and Cash Equivalents - End of Period 22,608,529 14,271,666 $ 18,186,506 $ 26,555,592
Supplemental Disclosures        
Depreciation and Amortization included in Research and Development Expense 574,511 $ 150,801    
Purchases of Fixed Assets included in Accounts Payable and Accrued Expenses $ 1,165,418